Key Updates
WMT has rebounded 2.52% since the initial report (from $104.87 to $107.52), driven by a 4.76% five-day rally that partially reverses the post-earnings sell-off. The most recent corporate developments—the settlement of the DOJ opioid lawsuit and the filing of the Q2 FY2027 10-Q—removed a legal overhang and confirmed previously reported financials (revenue +6% YoY to $186.1B, net income -9% YoY, diluted EPS $0.80). No new operational or guidance updates have emerged since the August 20 earnings release; the current bounce appears to be a technical recovery from oversold levels rather than a fundamental re-rating.
Current Trend
WMT remains in a broad downtrend on longer horizons but is showing near-term stabilization:
- 1-day: +1.34%; 5-day: +4.76% — sharp short-term reversal
- 1-month: -3.62% (improved from -5.69% in the prior report)
- 6-month: -15.94% (improved from -18.04%)
- YTD: -3.50%, still negative but off the post-earnings trough
The rebound follows the August 20 earnings-driven decline (shares fell 7-9% intraday, per CNBC and Forbes), suggesting the current move is a partial retracement rather than a change in trend direction.
Investment Thesis
The core thesis remains unchanged from the initial report: Walmart's scale, omnichannel investments, and diversified revenue streams (e-commerce, advertising, membership) support long-term resilience, but near-term margin and comparable-sales momentum have deteriorated. The company continues to gain share among higher-income households (Fortune) and is reinvesting tariff refunds into price competitiveness (WSJ), positioning for volume-led growth rather than near-term margin expansion.
Thesis Status
Thesis validity is mixed. Positive: raised FY2027 sales guidance (4-5% vs. prior 3.5-4.5%) and continued e-commerce/advertising strength confirm structural growth drivers remain intact (Reuters). Negative: comparable sales growth of 2.6% is the weakest in six years, missing consensus of 3.5-3.8%, and net income/EPS declined 9% YoY, confirming margin compression flagged in the initial report (SEC 10-Q). The resolution of the opioid litigation (CNBC) is a modest positive, removing a legacy legal risk, though settlement terms were undisclosed.
Key Drivers
- Q2 FY2027 comparable sales growth of 2.6%, the slowest in six years, driven by pharmacy pressure from Medicare drug pricing reform (Morningstar, Forbes)
- Net income -9% YoY and diluted EPS -9% YoY despite 6% revenue growth, indicating margin compression (SEC EDGAR)
- DOJ opioid lawsuit settlement, removing a multi-year legal overhang (CNBC)
- Raised FY2027 guidance for sales (4-5%) and adjusted EPS ($2.80-$2.87), supported by ~$2.9B in tariff refunds (Axios)
- New Q3 EPS guidance of $0.62-$0.64, below the $0.68 consensus, signaling continued near-term earnings pressure (Reuters)
- Strategic initiatives continuing: 11,000+ item price rollbacks (WSJ) and new "Scenario" fashion brand launch (WSJ)
Technical Analysis
WMT is rebounding sharply off its post-earnings low (implied ~$102.6, five sessions ago) toward the pre-earnings/one-month resistance zone near $111-112, which also corresponds to the approximate YTD starting level. The 4.76% five-day gain, combined with a positive 1-day move (+1.34%), indicates short-term bullish momentum and a potential oversold bounce; however, the stock remains below both its 1-month and YTD reference levels, and well below its 6-month starting point (~$128), confirming the broader downtrend is still intact. A sustained break above the $111-112 resistance band would be required to signal a trend reversal; failure to hold above the recent $102-103 support could reopen downside risk toward the post-earnings lows.
Bull Case
- Raised FY2027 sales growth guidance to 4-5% and adjusted EPS guidance to $2.80-$2.87, despite the Q2 comp-sales miss, signaling management confidence in the outlook (Reuters)
- E-commerce sales grew 24% and Walmart Connect (advertising) grew 43%, demonstrating diversification beyond traditional store sales (Reuters)
- Approximately $2.9 billion in expected tariff refunds provide margin flexibility to fund pricing investments without sacrificing profitability (Forbes)
- Settlement of the DOJ opioid lawsuit removes a significant multi-year legal risk from the pharmacy business (CNBC)
- Continued market share gains among higher-income households (>$100K) and new growth initiatives (Scenario fashion brand, expanded same-day delivery) broaden the addressable customer base (Fortune, WSJ)
Bear Case
- Q2 comparable sales growth of 2.6% is the slowest in six years and missed consensus estimates of 3.5-3.8%, described by analysts as "one of the biggest misses in years" (CNBC)
- Net income declined 9% YoY to $6.37 billion and diluted EPS fell 9% to $0.80, confirming margin compression despite top-line growth (SEC EDGAR)
- Pharmacy headwinds from Medicare drug price regulation are expected to persist into 2026, compounded by an anticipated $2 billion incremental cost headwind from higher fuel prices (Forbes)
- Consumer spending patterns show increased selectivity and trade-down behavior, with average transaction value growth slowing to 1.1% from 3.1% YoY, indicating discretionary spending pressure (Morningstar)
- Q3 EPS guidance of $0.62-$0.64 falls below the $0.68 analyst consensus, and this is the second consecutive quarter of decelerating comparable sales growth (Forbes)